Spark Therapeutics (ONCE) Misses Q3 EPS by 6c

Spark Therapeutics (NASDAQ: ONCE) reported Q3 EPS of ($1.07), $0.06 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Spark Therapeutics (ONCE) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance